A specialized subset of CD4 + T cells that can suppress inflammation and the responses of other T cells. These cells provide a crucial mechanism for the maintenance of peripheral self tolerance. A subset of these cells is characterized by expression of CD25 and the transcription factor FOXP3.
Although the link between inflammation and cancer has been noted for more than a century, investigators have only recently started to address the cellular, molecular and genetic causal relationships between these two events. Compelling evidence has shown that inflammation orchestrates the microenvironment around tumours, contributing to the proliferation, migration and survival of cancer cells that can result in tumour invasion, migration and metastasis. However, inflammatory reactions in the tumour microenvironment are an important component of the tumour-associated immune response. Inflammatory cells and molecules may have crucial roles in initiating and maintaining protective antitumour immunity. The specific nature of the inflammatory response and the tissue context may determine the beneficial versus the detrimental effects of inflammation on tumour pathology. T helper 17 (T H 17) cells are an important inflammatory component and have been shown to promote inflammation in a number of autoimmune diseases [1] [2] [3] [4] [5] [6] [7] [8] . Research on these cells is rapidly evolving, and recent reviews have extensively covered basic T H 17 cell biology, T H 17 cell lineage development and the relevance of T H 17 cells in autoimmune diseases [1] [2] [3] [4] 9, 10 . In this Review, we summarize recent reports of T H 17 cells in patients with cancer and in mouse tumour models. We examine the phenotype, recruitment, generation and function of tumour-associated T H 17 cells, focusing on their production of cytokines and on their interplay with other immune cells in the tumour microenvironment. Finally, we discuss the clinical relevance of T H 17 cells in tumour immunology and highlight their therapeutic potential.
T H 17 cells
Interleukin-17 (IL-17; originally termed CTLA8, also known as IL-17A) belongs to a family of six members (IL-17A, IL-17B, IL-17C, IL-17D, IL-17E and IL-17F) and has been of great interest recently owing to the discovery that the production of IL-17 characterizes a subset of CD4 + helper T cells (T H 17 cells). The development of T H 17 cells is distinct from the development of T H 1, T H 2 and regulatory T (T Reg ) cells and is characterized by unique transcription factors and cytokine requirements (FIG.1) . For further information on T H 17 lineage development, we refer the reader to some recent reviews [1] [2] [3] [4] 9 .
Tumour-associated T H 17 cells
Tissue distribution. It is well appreciated that T H 17 cells contribute to autoimmunity [1] [2] [3] [4] . However, one of the main physiological roles of T H 17 cells is to promote host defence against infectious agents, including certain bacteria, fungi, viruses and protozoa, and T H 17 cells are thought to be particularly important in maintaining barrier immunity at mucosal surfaces, such as the gut and lungs, as well as in the skin 11, 12 . Consistent with this, T H 17 cells are highly prevalent in the mucosal tissues of healthy individuals 11, 12 . More recently, T H 17 cells have been investigated in patients with diverse cancer types, including ovarian cancer and prostate cancer, and this list continues to grow (TABLE 1) . A caveat of these studies is that most have examined T H 17 cells in peripheral blood, rather than in the tumour itself. However, it is generally agreed that although T H 17 cells may remain a minor population in the peripheral blood of patients with cancer, 
Granzyme B
A secreted serine protease that enters target cells through perforin pores, it then cleaves and activates intracellular caspases, leading to target-cell apoptosis.
they can be more prevalent at the tumour site itself. Support for this has come from extensive study of the tissue distribution of T H 17 cells in patients with ovarian cancer. In these patients, the prevalence of T H 17 cells in tumour-draining lymph nodes and peripheral blood is similar to that found in the peripheral blood of healthy donors; however, higher proportions of T H 17 cells are found in tumours than at these other sites. This suggests that T H 17 cells may be induced in and/or recruited to the tumour microenvironment 13, 14 . In addition to these studies from human cancers, T H 17 cells are also found in mouse tumour models. Consistent with the findings from human tumours, T H 17 cells are more prevalent in the mouse tumour tissue itself, although T H 17 cells are generally present at lower frequencies than other T cell subsets 13 . In summary, although not the predominant T cell subset within the tumour, T H 17 cells are present in the tumour microenvironment.
Expression of tissue-homing molecules. Human primary tumour-infiltrating T H 17 cells isolated from colon carcinomas, hepatocellular carcinomas, melanoma, ovarian carcinoma, pancreatic cancers and renal cell carcinomas express high levels of CXC-chemokine receptor 4 (CXCR4), CC-chemokine receptor 6 (CCR6), several CD49 integrins and the C-type lectin receptor CD161 (also known as KLRB1), but do not express CD62L or CCR7 (REF. 14) . This suggests that these T H 17 cells do not home to lymphoid tissues, but some of the above homing molecules might be involved in T H 17 cell migration to, and retention within, inflammatory tissues and tumours [14] [15] [16] [17] 
Plasmacytoid dendritic cells
A subset of dendritic cells that is described as plasmacytoid because their microscopic appearance resembles plasmablasts. In humans, these cells can be derived from lineage-negative stem cells in peripheral blood and are the main producers of type I IFN in response to virus infections.
recruited from distal sites. Antigen-presenting cells (APCs), such as dendritic cells, induce T cell polarization into different effector T cell subsets (FIG. 1) . Although tumour-associated plasmacytoid dendritic cells isolated from ovarian cancers had minimal effect on T H 17 cell induction, tumour-associated macrophages and myeloid dendritic cells stimulated IL-17 production from memory T cells but not from naive T cells 14, 16, 26 . In addition, tumour-associated macrophages were shown to be more efficient than normal macrophages in eliciting T cell IL-17 production 14, 26 . As macrophages outnumber myeloid dendritic cells in many human cancers 18, 27 and are superior to myeloid dendritic cells in inducing T H 17 cells 14, 26 , macrophages might be the main inducers of T H 17 cells in the human tumour microenvironment.
Consistent with this possibility, tumour-associated macrophages expressed higher levels of IL-1β than normal tissue macrophages and normal monocytederived macrophages 14, 28 . IL-1β, but not IL-1α, IL-6, IL-23 or transforming growth factor-β (TGFβ), is crucial for T H 17 cell induction by human tumourassociated myeloid APCs 14 . Consistent with this observation, the levels of IL-1α and IL-23 are negligible in ovarian cancer ascites 14 . As IL-1α, IL-1β and IL-23 are involved in memory T H 17 cell expansion in patients with psoriasis 16, 26 , it is possible that the molecular mechanisms involved in inducing T H 17 cells in patients with tumours are different from those in patients with autoimmune diseases. The involvement of IL-6 and TGFβ in human T H 17 cell development remains controversial. It is suggested that TGFβ is essential for human T H 17 cell development [29] [30] [31] . However, high concentrations of TGFβ promote the development of T Reg cells and suppress T H 17 cell differentiation 29, 30, 32, 33 . High levels of IL-6 and TGFβ are often detected in the tumour microenvironment 34 . Therefore, if IL-6 and TGFβ have potent roles in promoting T H 17 cell induction, one might expect substantial numbers of T H 17 cells in human tumours. However, compared with the numbers of T Reg cells and other T cell subsets, the numbers of T H 17 cells present in both human and mouse tumours are limited 13 . Blockade of IL-1β, but not IL-6 or TGFβ, decreases T H 17 cell induction by myeloid APCs isolated from patients with ovarian cancer 14 . Furthermore, the levels of IL-17 and numbers of T H 17 cells do not correlate with IL-6 and TGFβ levels in patients with ovarian cancer 14 . Therefore, only IL-1β, but not IL-6 or TGFβ, seems to be crucial for T H 17 cell development in the ovarian cancer microenvironment. Recent mouse studies also support a crucial role for IL-1β in promoting T H 17 cell development 5, [35] [36] [37] . Thus, myeloid APCs can induce T H 17 cells in the human tumour microenvironment through IL-1β production 14 , but T H 17 cells in turn promote dendritic cell trafficking into tumour-draining lymph nodes and the tumour environment by producing CCL20. This chemokine can lead to the recruitment of dendritic cells to the tumour in a CCR6-dependent manner 17 . As human T H 17 cells also express high levels of CCR6 (REFS 14, 16) and efficiently migrate towards CCL20 (REF. 16), T H 17 cells might increase their own frequency in the tumour by both direct and indirect mechanisms. 65 , resulted in improved antitumour immunity.
In patients with prostate cancer, a significant inverse correlation is found between T H 17 cell differentiation and tumour progression 66 . Treatment with specific antibody against cytotoxic T lymphocyte antigen 4 (CTLA4) 67 induces T H 17 cells in patients with melanoma and the levels of IL-17 detected in tumour-associated ascites positively predicts patient survival. Taken together, these data provide strong evidence that T H 17 cells can have protective roles in tumour immunity. 14 . Levels of CXCL9 and CXCL10 were found to directly correlate with the number of tumour-infiltrating CD8 + T cells and NK cells. These data strongly suggest that T H 17 cells have an indirect role in antitumour immunity by promoting effector T cell and NK cell trafficking to, and retention within, the tumour microenvironment (FIG. 2) .
T H 17 cell-mediated antitumour activity could also be linked to dendritic cell recruitment into the tumour microenvironment or into tumour-draining lymph nodes. As mentioned above, T H 17 cells can stimulate CCL20 expression in tumour tissues and promote dendritic cell tumour trafficking in a CCL20-CCR6 dependent manner. In turn, CD8 + T cells are effectively primed and activated by dendritic cells and mediate potent antitumour immune responses. Altogether, these data suggest that T H 17 cells might not mediate direct antitumour activity, but can promote antitumour immunity indirectly through the recruitment of dendritic cells and cytotoxic effector cells 17 (FIG. 2) .
Pro-tumour role of T H 17 cell-associated cytokines IL-17 and T H 17 cells. Although IL-17 is the signature cytokine of T H 17 cells, the production of IL-17 is not the sole function of T H 17 cells. Thus, the biological activities of IL-17 should not be equated with the biological activities of T H 17 cells
. In addition to leukocytes of the immune system, the cellular targets of IL-17 in the tumour microenvironment can be vascular endothelial cells, stromal cells and cells of the tumour itself. Early studies showed that exogenous IL-17 could promote tumour growth by inducing tumour vascularization, particularly in immune-deficient nude mice and severe combined immunodeficient (SCID) mice [71] [72] [73] (TABLE 2) . However, the overall effect of IL-17 on tumour development and growth might be different in immune-competent hosts, as shown by the potent antitumour effects mediated by IL-17 in immune-competent mice 60, 61 (TABLE 2) . Furthermore, as a result of differences in local concentrations, bioavailability and potential targets, the biological activities of endogenous IL-17 (such as IL-17 derived from T H 17 cells) and exogenously administered IL-17 might differ. Two recent reports have shown that, in mice, endogenous IL-17 promotes Bacteroides fragilis-induced tumour formation 74 and tumour growth in a transplanted tumour model 75 . IL-17 induces IL-6 production by tumour cells and tumour-associated stromal cells, which in turn activates STAT3, an oncogenic transcription factor that upregulates pro-survival and pro-angiogenic genes 75 . Furthermore, although IL-17 deficiency leads to decreased numbers of IFNγ-producing NK cells in the tumour-draining lymph nodes of tumourbearing mice 59 , it has also been reported that IL-17 can decrease NK cell activity in a mouse model of dermatitis 76 . Therefore IL-17 can promote tumour growth in certain tumour-bearing mouse models, and the effects of IL-17 on tumour growth might be highly context dependent (BOX1; TABLE 2) .
IL-23 and T H 17 cells. IL-23
is an IL-12 cytokine family member, which is produced by APCs and promotes the expansion and survival of T H 17 cells. It has been reported that IL-23-deficient mice are resistant to chemically induced tumours 77 . This resistance is associated with decreased expression of matrix metalloproteinase 9 (MMP9) in the skin, a decrease in the expression of angiogenic markers and high levels of 
CD8
+ T cell infiltration. Given the close relationship between IL-23 and T H 17 cells, it has been proposed that T H 17 cells or IL-17 derived from T H 17 cells can promote tumorigenesis in this model.
However, this hypothesis remains to be tested and antitumour effects of IL-23 have been observed in several mouse tumour models [78] [79] [80] [81] [82] . Vaccination with IL-23-transduced dendritic cells 78 or overexpression of IL-23 at tumour sites has been shown to result in a robust infiltration of CD8 + T cells to the tumour and inhibition of tumour growth [79] [80] [81] . In addition, systemic administration of IL-23 suppressed the growth of a pre-existing fibrosarcoma in mice and resulted in increased survival 82 . Altogether, these data indicate that IL-23 might have distinct roles in antitumour immune responses and can either promote or inhibit tumorigenesis depending on the context of the experimental conditions (BOX1; TABLE 2).
Targeting T H 17 cells for cancer therapy
The involvement of T H 17 cells in the pathogenesis of various autoimmune diseases has been reviewed elsewhere [1] [2] [3] [4] [5] [6] [7] [8] 10 . It has been argued that cancer rejection can be viewed as intentional induction of autoimmune disease 83 . The antitumour activities of CD8 + T cells have received the most attention in the field of tumour immunology; these cells produce IFNγ, GM-CSF and TNF and can specifically lyse antigen-presenting MHC class I + tumours. The infusion of large numbers of tumour-specific CD8 + T cells, expanded in vitro with IL-2, can induce the regression of large tumour burdens in mice and in humans 84 . However, the use of CD4 + helper T cell subsets in tumour immunotherapy has been under-explored, especially in the clinic. This can be attributed partly to the massive diversity of the MHC class II loci and partly to the complexity of CD4 + helper T cell subtypes in mice and humans.
Box 1 | T H 17 cell biology and important research contexts
The biological activities of T helper 17 (T H 17) cells and the T H 17 cell-associated cytokines (interleukin-17 (IL-17) and IL-23) may be highly context dependent. The following aspects could be crucial for our understanding of the antitumour versus pro-tumour activities of IL-17 and/or T H 17 cells.
Exogenous versus endogenous IL-17
The findings that IL-17 can have pro-tumorigenic or antitumorigenic activity might be due, in part, to the source of IL-17 in each of the studies. Exogenously delivered IL-17 might differ in dose from endogenous IL-17 that is produced by T H 17 cells and other IL-17-expressing cells. Therefore, the biological activities of exogenous versus endogenous IL-17 might not be identical (TABLE 2) .
IL-17
+ cell populations IL-17 can be produced by T H 17 cells, CD8 + T cells, natural killer T (NKT) cells and osteoclasts [1] [2] [3] [4] 104 . The biological activities of IL-17 made by different cell types may not be identical owing to the different levels of IL-17 and other contexts, including localization, cytokine profile and cellular environments. [17] [18] [19] [20] [21] [22] [23] .
T H 17 cell subsets

T H 17 cell cytokine profile
The function of T H 17 cells may not be solely determined by IL-17. In addition to IL-17, tumour T H 17 cells can express many cytokines, including IL-2, IL-9, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-γ (IFNγ) and tumour necrosis factor (TNF) 14, 15, 23 . These cytokines may synergize with IL-17 to mediate biological activities. For example, IFNγ and IL-17 derived from T H 17 cells synergistically induce β-defensin 2 and T H 1-type chemokines 14, 16 .
T H 17 cells and associated cytokines
Several cytokines are associated with T H 17 cell development. The role of IL-23 is controversial in the context of tumour pathology. Although IL-23 is involved in regulating T H 17 cell development, the biological activities of IL-23 should not necessarily be associated with only T H 17 cell activity [77] [78] [79] [80] [81] [82] (TABLE 2) . 
Cellular targets
Research models
The research models can be human subjects or animals, immune-competent or immune-deficient hosts, and subjects with or without chemical or infection-associated inflammation. The role of IL-17 in tumorigenesis might depend on the research model used. For example, IL-17 can be pro-tumorigenic in immune-deficient models [71] [72] [73] but has been shown to have antitumorigenic properties in immune-competent models 60, 61 .
Disease stages
Human tumorigenesis is often a slow process that occurs over many years. Immune responses are likely to be dynamically altered in the tumour microenvironment at different stages of tumour development 14, 66 . Mouse tumour models may not represent a satisfactory model for dissecting the nature of human tumours at specific stages (TABLES 1, 2 Efforts to use polarized helper T cell subsets in the clinic to induce tumour regression have been minimal. Although a single case study reported a dramatic antitumour response in a patient treated with ex vivo generated autologous CD4 + T cell clones, which recognized the tumour-associated antigen NY-ESO1 (REF. 91 ), these cells were not specifically polarized to any helper T cell subset. Based on the data from animal models, the treatment of patients with cancer with T H 17-polarized T cells seems to be a promising approach; however, at the time of writing, there have been no published reports on the use of T H 17 cells to treat any human cancer. Given our knowledge of human tumour systems, it seems plausible that a clinical trial involving the adoptive transfer of T H 17-polarized, tumour-specific T cells could be carried out. One credible trial design involves the polarization of naive human T cells using a cocktail of cytokines, such as IL-1β, IL-6, IL-21, IL-23, TGFβ and TNF 92 . Recombinant gammaretroviruses or lentiviruses that encode genes for tumour antigen-specific T cell receptors or chimeric antigen receptors could be used to confer antitumour activity onto autologous, T H 17-polarized T cells. Similar to the strategy that has been used for genetically engineered CD8 + T cells, the resulting T H 17 cells could be expanded to large numbers in vitro and then transferred back into patients with cancer 93 .
Concluding remarks
Despite the recent identification of T H 17 cells, over the past few years we have made rapid and large advances in our understanding of the development, regulation and function of these cells. This has been particularly true in the context of autoimmune diseases, where the pathogenic role of T H 17 cells has been well documented. However, the exact nature of T H 17 cells in antitumour immunity is not a 'black and white' picture: the roles of T H 17 cells in tumorigenesis are best represented by many colours. T H 17 cells and T H 17-associated cytokines have been shown to have both antitumorigenic and pro-tumorigenic functions. Therefore, the relationship between T H 17 cells and tumour immunopathology are highly dependent on context (BOX1), but a better understanding of these contexts could be used to develop and refine new cancer therapies. 
